On Monday, Praxis disclosed a late-stage failure for its investigational seizure medicine, and the company is pausing enrollment in a second trial while it figures out what to do.
Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins.
But on Monday, the company …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Why Is Praxis Stock Plunging Today - Praxis Precision Medicine (NASDAQ:PRAX)
Axsome fends off generic competition to narcolepsy med Sunosi until 2040
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
Why Polaryx Therapeutics Stock Is Surging On Thursday? - Polaryx Therapeutics (NASDAQ:PLYX)
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Psilera Closes Oversubscribed $8.8M Seed Funding Round to Accelerate Neuroplastogen PSIL-006 Into the Clinic
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
Early trials have shown a massive reduction in seizures among young people with Dravet syndrome
Parabilis Medicines, the decade-old and well-funded
